The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

idenix.com

Founded Year

1998

Stage

Acq - P2P | Acquired

Total Raised

$68.91M

Valuation

$0000 

Revenue

$0000 

About Idenix Pharmaceuticals

Idenix Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix is headquartered in Cambridge, Massachusetts (USA). The Company's clinical development operations and drug discovery operations are conducted in Cambridge and in the Company's European laboratories in Montpellier, France. Idenix's current focus is on the treatment of patients with hepatitis C infection.

Idenix Pharmaceuticals Headquarter Location

320 Bent Street 4th Floor

Cambridge, Massachusetts, 02141,

United States

617-995-9800

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Idenix Pharmaceuticals Patents

Idenix Pharmaceuticals has filed 79 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Experimental drugs
  • HIV/AIDS
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/19/2017

9/21/2021

Molecular biology, Hepatotoxins, HIV/AIDS, Virology, Experimental drugs

Grant

Application Date

12/19/2017

Grant Date

9/21/2021

Title

Related Topics

Molecular biology, Hepatotoxins, HIV/AIDS, Virology, Experimental drugs

Status

Grant

Latest Idenix Pharmaceuticals News

Hepatitis C Virus (HCV) Protease Inhibitor Drug Pipeline Market Research Report 2022 Featuring MetalloPharm, Anacor Pharmaceuticals, GSK, Concert Pharmaceuticals, Idenix Pharmaceuticals, & Genoscience - ResearchAndMarkets.com

Feb 3, 2022

"Hepatitis C Virus (HCV) Protease Inhibitor - Pipeline Insight, 2022" offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Hepatitis C Virus (HCV) Protease Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Descriptive coverage of pipeline development activities for Hepatitis C Virus (HCV) Protease Inhibitor Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for Hepatitis C Virus (HCV) Protease Inhibitor The report assesses the active Hepatitis C Virus (HCV) Protease Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route. Scope of the Report Provides a snapshot of the therapeutics pipeline activity for Hepatitis C Virus (HCV) Protease Inhibitor Features the Hepatitis C Virus (HCV) Protease Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Hepatitis C Virus (HCV) Protease Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Hepatitis C Virus (HCV) Protease Inhibitor Key Topics Covered:

  • When was Idenix Pharmaceuticals founded?

    Idenix Pharmaceuticals was founded in 1998.

  • Where is Idenix Pharmaceuticals's headquarters?

    Idenix Pharmaceuticals's headquarters is located at 320 Bent Street, Cambridge.

  • What is Idenix Pharmaceuticals's latest funding round?

    Idenix Pharmaceuticals's latest funding round is Acq - P2P.

  • How much did Idenix Pharmaceuticals raise?

    Idenix Pharmaceuticals raised a total of $68.91M.

  • Who are the investors of Idenix Pharmaceuticals?

    Investors of Idenix Pharmaceuticals include Merck & Co., Novartis, MPM Capital, Nomura Holdings, TVM Capital and 9 more.

  • Who are Idenix Pharmaceuticals's competitors?

    Competitors of Idenix Pharmaceuticals include Achillion Pharmaceuticals, Innate Pharma, BioMarck Pharmaceuticals, Alios BioPharma, ViroPharma, Excaliard Pharmaceuticals, Anadys Pharmaceuticals, Cellectar Biosciences, Affectis Pharmaceuticals, Metabasis Therapeutics and 17 more.

You May Also Like

N
Need Pharma

NeED Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of anti-infective drugs for the treatment of serious and neglected infectious diseases, where a large unmet medical need and market opportunity are clearly present.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

D
Deltanoid Pharmaceuticals

Deltanoid Pharmaceuticals is a clinical stage biopharmaceutical company with a vision focused on unlocking the power of the vitamin D receptor (VDR) to transform health outcomes for patients with diseases of the kidney, bone, and skin.

REPLICor Logo
REPLICor

REPLICor is a biopharmaceutical company developing first-in-class entry inhibitors for the treatment of hepatitis C (HCV) and prevention of HCV re-infection following liver transplantation. The company also targets the hepatitis B and influenza markets. The lead compound REP 9AC is a broad-spectrum antiviral having potent activity against HCV, HBV, influenza and other enveloped viruses. The compound is active by multiple routes of administration and is well tolerated. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its product.

A
Affectis Pharmaceuticals

Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.

I
Inflazyme Pharmaceuticals

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.